Literature DB >> 8487491

The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria.

H H Kecskemethy1, D Lobbregt, H L Levy.   

Abstract

Maternal phenylketonuria (PKU) represents a high risk for birth defects, including mental retardation, in offspring. Thus, it could cancel gains represented by the prevention of PKU-induced mental retardation in the current generation. Effective dietary treatment of maternal PKU pregnancies could avoid this potentially tragic occurrence. However, dietary compliance is often difficult because a necessary component of the diet, medical nutritional formulas, often have an unpleasant taste and odour. We treated the second pregnancy of a phenylketonuric women who had required extended hospitalization during her first pregnancy because of poor formula tolerance, and who had similar difficulty in the second pregnancy. To alleviate this problem, we developed a system whereby she could pack the formula into gelatin capsules for ingestion. Packing and ingestion of 20 capsules required less than 30 minutes three times a day. With capsules her blood phenylalanine level was almost always within the recommended range of 120-360 mumol/L (2-6 mg/dl) and hospitalization was not required. The phenylalanine content of the capsules was easily accommodated by a small reduction in allowable food. Other amino acid levels, including tyrosine and other essential nutrient levels, were normal. We believe that using gelatin capsules for formula ingestion can be very beneficial in the management of maternal PKU pregnancies and could be extended to the dietary treatment of other inborn errors of metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8487491     DOI: 10.1007/bf00711324

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  8 in total

1.  Diet discontinuation policies and practices of PKU clinics in the United States.

Authors:  V E Schuett; R F Gurda; E S Brown
Journal:  Am J Public Health       Date:  1980-05       Impact factor: 9.308

2.  A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada.

Authors:  R Koch; W Hanley; H Levy; R Matalon; B Rouse; F Dela Cruz; C Azen; E Gross Friedman
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

3.  Maternal phenylketonuria--results of dietary therapy.

Authors:  R R Lenke; H L Levy
Journal:  Am J Obstet Gynecol       Date:  1982-03-01       Impact factor: 8.661

4.  Experience with adolescents with phenylketonuria returned to phenylalanine-restricted diets.

Authors:  S E Hogan; R D Gates; G W MacDonald; J T Clarke
Journal:  J Am Diet Assoc       Date:  1986-09

5.  Timing of strict diet in relation to fetal damage in maternal phenylketonuria. An international collaborative study by the MRC/DHSS Phenylketonuria Register.

Authors:  E Drogari; I Smith; M Beasley; J K Lloyd
Journal:  Lancet       Date:  1987-10-24       Impact factor: 79.321

6.  Projections of a rebound in frequency of mental retardation from phenylketonuria.

Authors:  H N Kirkman
Journal:  Appl Res Ment Retard       Date:  1982

7.  Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies.

Authors:  R R Lenke; H L Levy
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

8.  Reinstitution of diet therapy in PKU patients from twenty-two US clinics.

Authors:  V E Schuett; E S Brown; K Michals
Journal:  Am J Public Health       Date:  1985-01       Impact factor: 9.308

  8 in total
  2 in total

1.  Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria.

Authors:  F J Rohr; A W Munier; H L Levy
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

2.  Are tablets a practical source of protein substitute in phenylketonuria?

Authors:  A MacDonald; C Ferguson; G Rylance; A A M Morris; D Asplin; S K Hall; I W Booth
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.